Open: 139.25 Close: 138.88 Change: -0.37

Today's Summary

1 in 4 metastatic breast cancer patients treated with novartis kisqali® remain progression-free beyond 4 years. 1 in four metastatic. breast cancer. patients treated. with Novartis Kisqali. remain progression free beyond four years. Novartis has gained 24.1% since the start of the year compared to the -1.5% move for the Zacks Medical sector and the 2.8% return for Zacks Large Cap Pharmaceuticals industry. Shares of Novartis have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+38.8% vs. the ZACK Pharmaceuticals) Shares of Air T, Inc. outperformed Zacks Aerospace - Defense industry (+54.1%)